Pharma BD Deal Intelligence

Bayer AG / Asklepios BioPharmaceutical, Inc. (AskBio)

2020 · Acquisition/Merger · $4.0B · Complete

Announcement Sentiment

Strongly positive

Bayer agreed to acquire Asklepios BioPharmaceutical (AskBio) for $2B upfront plus up to $2B in success-based milestones (~75% expected within five years). Brought industry-leading AAV gene therapy platform with proprietary Pro10 manufacturing and extensive AAV capsid/promoter library. Lead clinical programs in Pompe disease, Parkinson's, and congestive heart failure. AskBio operates independently post-close.

Did it work? Outcome assessment

Strategic verdict

Too Early

Financial impact

Neutral

Pipeline outcome

Assets Advanced

Assessment window: 5yr post-close.

Key facts

Announced Oct 26, 2020
Closed Dec 21, 2020
Deal value $4.0B
Deal type Acquisition/Merger
Therapeutic area Neuromuscular, CNS, cardiovascular and metabolic diseases
Indications Neuromuscular, CNS, cardiovascular and metabolic diseases
Key assets AAV gene therapy platform; Pompe disease, Parkinson's disease, congestive heart failure programs
Mechanism Adeno-associated virus (AAV)-based gene therapy

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals